Abstract

The invention refers to the use of an engineered ‘Clustered Regularly Interspersed Short Palindromic Repeat (CRISPR)-CRISPR associated (Cas)’ (CRISPR-Cas) technology targeting a sequence mutated at one or more loci in the genome of a given eukaryotic cell

Research Institution

Università degli Studi di Siena

Numero di pubblicazione

WO2020127272A1

TRL

3

Technologies, Systems, Applications

Biotechnologies, New drugs development